Diagnosis of Gestational Diabetes Based on a 50-gram Glucose Challenge
Study Overview
Status
Status
Conditions
Conditions
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
Texas
-
Dallas, Texas, United States, 75203
- Clinical Research Institute at Methodist Health System
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Singleton pregnancies in which a 3-hour, 100-gram glucose test was completed and failed after 24-weeks' gestation.
Exclusion Criteria:
- Pregnancies with multiple gestations, glucose tests prior to 24 weeks', or those with incomplete 50-gram or 100-gram screening records.
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Determine if there is glucose value after the 50-gram oral GTT that can be used to diagnose gestational diabetes
Time Frame: through study completion, up to 18 months
|
The primary outcome will be the 50-gram glucose results for patients that were diagnosed with gestational diabetes by a 100-gram glucose challenge.
|
through study completion, up to 18 months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Margaret Warren, DO, MFM, Physician
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- 017.MFM.2023.D
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.